Cytokine Signalling Forum
CME Courses
The Evolving Landscape of Small Molecule Inhibitors in Rheumatoid Arthritis
This activity is supported by unrestricted educational grants from Lilly
Expiration date: 24 September 2021
Estimated time to complete activity: 1 and 1/2 hours
Compatible with all modern internet browsers and mobile devices
EDUCATIONAL OBJECTIVES
After completing this activity, the learner will be able to:
- Review the updated safety data for approved JAK inhibitors
- Review the data on JAK inhibitors in development
- Discuss the biology of BTK inhibitors and their potential in the treatment of rheumatoid arthritis
TARGET AUDIENCE
This activity is designed for rheumatologists and other healthcare professionals involved in treating patients with rheumatic disease.
PROGRAMME OVERVIEW
This programme presents new research into cytokine signalling with a focus on approved and emerging JAK and BTK inhibitors, which are set to shape the ever-changing rheumatology treatment landscape. JAK inhibitors are now being marketed for the treatment of rheumatoid arthritis, with new JAK inhibitors on the horizon and new data for new cytokine signaling agents emerging. With ever evolving comparisons between current drugs and new agents in the pipeline, there is an educational need to keep up-to-date with ongoing research to understand the impact the latest data has on clinical practice.
In this activity, The Evolving Landscape of Small Molecule Inhibitors in Rheumatoid Arthritis, a panel of international experts discuss some of the latest papers and key abstracts from EULAR 2019 with a focus on cytokine signalling. Data, presented in 3 distinct modules, highlights JAK inhibitors in clinical practice, emerging JAK inhibitors in phase 3 trials and the potential of new BTK inhibitors as a new treatment for rheumatoid arthritis. The learner’s understanding of the information presented will be assessed following each of the course modules.
INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational content; 3) successfully complete the post-module assessments with a score of ≥80%; 4) complete the evaluation form. Upon completion of the full activity, a certificate will be made available to download and print.
DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.
ACCREDITATION STATEMENT
The e-learning activity, The Evolving Landscape of Small Molecule Inhibitors in Rheumatoid Arthritis, organised by CESAS Medical, under the auspices of the University of Glasgow, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The e-learning activity, The Evolving Landscape of Small Molecule Inhibitors in Rheumatoid Arthritis, organised by CESAS Medical, under the auspices of the University of Glasgow, is awarded 1 European CME credits (ECMECs) .
Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
| Module | Presenter | Video | Questions |
|---|---|---|---|
| Introduction |
Professor Iain B. McInnes
Vice Principal and Head of College of Medical, Veterinary and Life Sciences (MVLS) President of European Alliance of Associations for Rheumatology (EULAR), Professor Iain McInnes is the Vice Principal and Head of College of MVLS in the University of Glasgow, UK. He is also the current President of the EULAR, the leading trans-national society for rheumatology across Europe. Professor McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA. He has extensive experience in leading multicentre programmes, nationally and internationally. Professor McInnes is also Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Programme; Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery programme (PROMISERA); and Chief Investigator of numerous global phase II and III clinical trials of novel immune therapies His major interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He operates on a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics thereafter. He received the Sir James Black Prize Medal, a prestigious award in medicine in 2016 by the Royal Society of Edinburgh for his outstanding contribution to the field of immunology. In 2019, Professor McInnes was awarded a CBE for his services to Medicine. |
06:37 | |
| JAKinibs in Clinical Practice |
Professor Johannes W.J. Bijlsma
Professor and Head of the Department of Rheumatology and Clinical Immunology, Professor Bijlsma is the past President of EULAR (2017-2019), and a Professor of Rheumatology at the University Medical Centre, Utrecht, The Netherlands. He acquired his Medical degree and PhD from the University of Utrecht and has been a Professor of Rheumatology since 1990. Professor Bijlsma was the Chairman of The EULAR Standing Committee on Education and Training, EULAR Educational Officer and has been EULAR Treasurer. He has also held a variety of roles from 1992-2008 at the Dutch Society for Rheumatology, including Scientific Secretary, President and Chairman Consilium. He is chairman of the Advisory Board of the Annals of Rheumatic Diseases and is on the editorial board of Clinical and Experimental Rheumatology, Best Practice & Research Clinical Rheumatology and Clinical Rheumatology. Professor Bijlsma researches and specialises in immune aspects of rheumatic diseases and Osteoarthritis. He has authored and co-authored over 800 articles published in peer-reviewed international journals, has contributed chapters in a number of textbooks, and has edited and co-edited several books in the field of Rheumatology, including the EULAR Textbooks. |
22:55 | 5 |
| Emerging JAKinibs |
Professor Iain B. McInnes
Vice Principal and Head of College of Medical, Veterinary and Life Sciences (MVLS) President of European Alliance of Associations for Rheumatology (EULAR), Professor Iain McInnes is the Vice Principal and Head of College of MVLS in the University of Glasgow, UK. He is also the current President of the EULAR, the leading trans-national society for rheumatology across Europe. Professor McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA. He has extensive experience in leading multicentre programmes, nationally and internationally. Professor McInnes is also Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Programme; Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery programme (PROMISERA); and Chief Investigator of numerous global phase II and III clinical trials of novel immune therapies His major interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He operates on a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics thereafter. He received the Sir James Black Prize Medal, a prestigious award in medicine in 2016 by the Royal Society of Edinburgh for his outstanding contribution to the field of immunology. In 2019, Professor McInnes was awarded a CBE for his services to Medicine. |
45:53 | 13 |
| Beyond JAKinibs: Potential New Cytokine Signalling Pathways |
Professor Johannes W.J. Bijlsma
Professor and Head of the Department of Rheumatology and Clinical Immunology, Professor Bijlsma is the past President of EULAR (2017-2019), and a Professor of Rheumatology at the University Medical Centre, Utrecht, The Netherlands. He acquired his Medical degree and PhD from the University of Utrecht and has been a Professor of Rheumatology since 1990. Professor Bijlsma was the Chairman of The EULAR Standing Committee on Education and Training, EULAR Educational Officer and has been EULAR Treasurer. He has also held a variety of roles from 1992-2008 at the Dutch Society for Rheumatology, including Scientific Secretary, President and Chairman Consilium. He is chairman of the Advisory Board of the Annals of Rheumatic Diseases and is on the editorial board of Clinical and Experimental Rheumatology, Best Practice & Research Clinical Rheumatology and Clinical Rheumatology. Professor Bijlsma researches and specialises in immune aspects of rheumatic diseases and Osteoarthritis. He has authored and co-authored over 800 articles published in peer-reviewed international journals, has contributed chapters in a number of textbooks, and has edited and co-edited several books in the field of Rheumatology, including the EULAR Textbooks. |
18:35 | 4 |
| Close |
Professor Iain B. McInnes
Vice Principal and Head of College of Medical, Veterinary and Life Sciences (MVLS) President of European Alliance of Associations for Rheumatology (EULAR), Professor Iain McInnes is the Vice Principal and Head of College of MVLS in the University of Glasgow, UK. He is also the current President of the EULAR, the leading trans-national society for rheumatology across Europe. Professor McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA. He has extensive experience in leading multicentre programmes, nationally and internationally. Professor McInnes is also Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Programme; Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery programme (PROMISERA); and Chief Investigator of numerous global phase II and III clinical trials of novel immune therapies His major interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He operates on a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics thereafter. He received the Sir James Black Prize Medal, a prestigious award in medicine in 2016 by the Royal Society of Edinburgh for his outstanding contribution to the field of immunology. In 2019, Professor McInnes was awarded a CBE for his services to Medicine.
Professor Johannes W.J. Bijlsma
Professor and Head of the Department of Rheumatology and Clinical Immunology, Professor Bijlsma is the past President of EULAR (2017-2019), and a Professor of Rheumatology at the University Medical Centre, Utrecht, The Netherlands. He acquired his Medical degree and PhD from the University of Utrecht and has been a Professor of Rheumatology since 1990. Professor Bijlsma was the Chairman of The EULAR Standing Committee on Education and Training, EULAR Educational Officer and has been EULAR Treasurer. He has also held a variety of roles from 1992-2008 at the Dutch Society for Rheumatology, including Scientific Secretary, President and Chairman Consilium. He is chairman of the Advisory Board of the Annals of Rheumatic Diseases and is on the editorial board of Clinical and Experimental Rheumatology, Best Practice & Research Clinical Rheumatology and Clinical Rheumatology. Professor Bijlsma researches and specialises in immune aspects of rheumatic diseases and Osteoarthritis. He has authored and co-authored over 800 articles published in peer-reviewed international journals, has contributed chapters in a number of textbooks, and has edited and co-edited several books in the field of Rheumatology, including the EULAR Textbooks. |
01:03 | |
| Evaluation | 17 |
Date of preparation: 30 August 2019